At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
08329 NEP INTERLONG
Closed 04-24 15:56:25
0.130
+0.001
+0.78%
High0.129Low0.121Vol30.00K
Open0.129D1 Closing0.129Amplitude6.20%
Mkt Cap218.14MTradable Cap55.38MTotal Shares1.68B
T/O3.79KT/O Rate0.01%Tradable Shares426.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
NEP INTERLONG Reports 2025 Fiscal Year Results with Shareholder Loss of 40.74 Million Yuan
Stock News  ·  03-25
NEP INTERLONG Reports 2025 Fiscal Year Results with Shareholder Loss of 40.74 Million Yuan
Neptunus Interlong posts FY2025 net loss of RMB53.10 million on weaker revenue and impairment charge
Bulletin Express  ·  03-25
Neptunus Interlong posts FY2025 net loss of RMB53.10 million on weaker revenue and impairment charge
Shenzhen Neptunus Interlong Bio-Technique - FY Revenue RMB972 Mln
THOMSON REUTERS  ·  03-25
Shenzhen Neptunus Interlong Bio-Technique - FY Revenue RMB972 Mln
Shenzhen Neptunus Interlong Bio-Technique - Loss and Total Comprehensive Expenses for Year Attributable RMB 40.7 Mln
THOMSON REUTERS  ·  03-25
Shenzhen Neptunus Interlong Bio-Technique - Loss and Total Comprehensive Expenses for Year Attributable RMB 40.7 Mln
Shenzhen Neptunus Interlong Bio-Technique FY2025 operating income drops to a RMB44 million operating loss; revenue falls 6.69% to RMB972 million
Reuters  ·  03-25
Shenzhen Neptunus Interlong Bio-Technique FY2025 operating income drops to a RMB44 million operating loss; revenue falls 6.69% to RMB972 million
Neptunus Interlong projects RMB40.00 million net loss for 2025, swinging from prior-year profit
Bulletin Express  ·  03-24
Neptunus Interlong projects RMB40.00 million net loss for 2025, swinging from prior-year profit
NEP INTERLONG Anticipates Approximately RMB 40 Million Net Loss Attributable to Owners for Fiscal Year 2025
Stock News  ·  03-24
NEP INTERLONG Anticipates Approximately RMB 40 Million Net Loss Attributable to Owners for Fiscal Year 2025
Shenzhen Neptunus Interlong Bio-Technique - Sees FY Net Loss Attributable of RMB40 Mln
THOMSON REUTERS  ·  03-24
Shenzhen Neptunus Interlong Bio-Technique - Sees FY Net Loss Attributable of RMB40 Mln
Shenzhen Neptunus Interlong forecasts 2025 net loss of RMB40 million
Reuters  ·  03-24
Shenzhen Neptunus Interlong forecasts 2025 net loss of RMB40 million
BRIEF-Shenzhen Neptunus Interlong Bio-Technique Sees Decrease In Profit Attributable For Year
Reuters  ·  03-20
BRIEF-Shenzhen Neptunus Interlong Bio-Technique Sees Decrease In Profit Attributable For Year
NEP Interlong (08329) Expects 240%–280% Profit Decline for FY2025 Due to Goodwill Impairment
Bulletin Express  ·  03-20
NEP Interlong (08329) Expects 240%–280% Profit Decline for FY2025 Due to Goodwill Impairment
NEP INTERLONG (08329) Forecasts 240% to 280% Drop in Annual Profit Attributable to Owners for 2025
Stock News  ·  03-20
NEP INTERLONG (08329) Forecasts 240% to 280% Drop in Annual Profit Attributable to Owners for 2025
Shenzhen Neptunus Interlong Bio-Technique Sees Decrease of 240% to 280% in Profit Attributable for Year
THOMSON REUTERS  ·  03-20
Shenzhen Neptunus Interlong Bio-Technique Sees Decrease of 240% to 280% in Profit Attributable for Year
Shenzhen Neptunus Interlong expects profit attributable to owners to fall about 240% to 280% in 2025
Reuters  ·  03-20
Shenzhen Neptunus Interlong expects profit attributable to owners to fall about 240% to 280% in 2025
NEP INTERLONG (08329) Sets 25 Mar 2025 Board Meeting to Approve FY2025 Results and Consider Final Dividend
Bulletin Express  ·  03-11
NEP INTERLONG (08329) Sets 25 Mar 2025 Board Meeting to Approve FY2025 Results and Consider Final Dividend
BRIEF-Shenzhen Neptunus Interlong Bio-Technique Expects 80%-120% Decrease In Profit Attributable For Year
Reuters  ·  03-10
BRIEF-Shenzhen Neptunus Interlong Bio-Technique Expects 80%-120% Decrease In Profit Attributable For Year
NEP INTERLONG (08329) Issues Profit Warning, Forecasts 80%-120% Decline in Annual Profit Attributable to Shareholders
Stock News  ·  03-10
NEP INTERLONG (08329) Issues Profit Warning, Forecasts 80%-120% Decline in Annual Profit Attributable to Shareholders
Shenzhen Neptunus Interlong warns 2025 owner profit may fall 80% to 120%
Reuters  ·  03-10
Shenzhen Neptunus Interlong warns 2025 owner profit may fall 80% to 120%
Shenzhen Neptunus Interlong Bio-Technique - Expects 80%-120% Decrease in Profit Attributable for Year
THOMSON REUTERS  ·  03-10
Shenzhen Neptunus Interlong Bio-Technique - Expects 80%-120% Decrease in Profit Attributable for Year
Shenzhen Neptunus Interlong Bio-Technique - Expected Result Due to Provision for Impairment of Goodwill From Recent Acquisition
THOMSON REUTERS  ·  03-10
Shenzhen Neptunus Interlong Bio-Technique - Expected Result Due to Provision for Impairment of Goodwill From Recent Acquisition

Introduction

Company Name.
NEP INTERLONG
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Shenzhen Neptunus Interlong Bio-technique Co Ltd is a China-based company principally engaged in the research and development, manufacturing and selling of medicines and medical devices, and the purchase and sales of medicines, healthcare food products and medical devices. The Company operates its businesses through two segments. The Manufacturing and Selling of Medicines and Medical Devices segment is mainly engaged in manufacturing, sales of medicines and medical devices. The Sales and Distribution of Medicines, Healthcare Products and Medical Devices segment is mainly engaged in sales and distribution of medicines, healthcare products and medical devices. The Company mainly operates its businesses in the domestic market.
Issue price:
--